Therakine was founded in 2004 when a widely respected physician discovered better treatments for children who were rapidly losing their eyesight due to chronic inflammatory eye disease.

Frustrated by the limitations of existing systemic delivery systems, the TheraKine team soon decided that a local, targeted approach to delivery would produce a much more effective and efficient outcome for the patient. This work continues, with exciting results in feasibility trials. TheraKine estimates that the first human clinical trials will start in the fourth quarter of 2009.

For information contact info@therakine.com or call 678-648-4037